Price$0.67+0.02 (+3.06%)
04:30 PM06:15 PM
News · 26 weeks47+22%
2026-01-252026-07-19
Mix2590d
- SEC Filings11(44%)
- Insider7(28%)
- Other4(16%)
- Earnings2(8%)
- Offering1(4%)
Latest news
25 items- PRPresenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live streamMIAMI, July 15, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday July 15, 2026 11:00Virtual Lobby opens.Register for the Conference. If you already registered
- PRAethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohortsSAN DIEGO, July 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first cohort following treatment with the investigational Hemopurifier®. Replicating these findings in a second group of patients strengthens the scientific rationale for the Co
- SECAethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form 424B3 filed by Aethlon Medical Inc.424B3 - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form EFFECT filed by Aethlon Medical Inc.EFFECT - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesSAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 5,633,009 shares of its common stock at a combined public offering price of $0.7101 per share (or pre-funded warrant) and accompanying warrant, priced at-the-market under applicable Nasdaq rules. The warrants will have an exercise price of $0.7101 per share, will be exercisable upon the date of stockholder approval, and
- INSIDERDirector Shah Chetan covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 9% to 20,840 units (SEC Form 4) (withholding obligation)4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERDirector Gikakis Nicolas covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 10% to 20,663 units (SEC Form 4) (tax liability)4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERDirector Broenniman Edward G covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 5% to 22,363 units (SEC Form 4) (for withholding tax)4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- SECAmendment: SEC Form S-1/A filed by Aethlon Medical Inc.S-1/A - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAmendment: SEC Form S-1/A filed by Aethlon Medical Inc.S-1/A - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatmentSAN DIEGO, June 26, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin in
- SECSEC Form S-1 filed by Aethlon Medical Inc.S-1 - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form S-8 filed by Aethlon Medical Inc.S-8 - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form 10-K filed by Aethlon Medical Inc.10-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECAethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate UpdateAustralian oncology study advances into Cohort 3 as enrollment continuesEntered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses.Conference Call Today at 4:30 p.m. ETSAN DIEGO, June 10, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments. Key Highlight
- SECAethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - AETHLON MEDICAL INC (0000882291) (Filer)
- SECSEC Form 424B5 filed by Aethlon Medical Inc.424B5 - AETHLON MEDICAL INC (0000882291) (Filer)
- PRAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year end March 31, 2026, at 4:15 p.m. ET on Wednesday, June 10, 2026. Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10209612/1042263e8ec. Please note t
- PRAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic PreparednessSAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology. According to recent reports from the World Health Organization ("WHO") and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of
- INSIDERSEC Form 4 filed by Gikakis Nicolas4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Broenniman Edward G4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Rossetti Angela4 - AETHLON MEDICAL INC (0000882291) (Issuer)
- INSIDERSEC Form 4 filed by Shah Chetan4 - AETHLON MEDICAL INC (0000882291) (Issuer)
AEMD FAQ
6 questionsWhat does Aethlon Medical Inc. do?
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for...Where does AEMD stock trade?
Aethlon Medical Inc. (AEMD) is listed on NASDAQ.What sector and industry is AEMD in?
Aethlon Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about AEMD?
Aethlon Medical Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $150.00 price target on 2025-07-07.What companies are similar to AEMD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare AEMD side-by-side with any of them on Quantisnow.How can I track AEMD on Quantisnow?
Quantisnow aggregates Aethlon Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AEMD to receive live email and push alerts on every new disclosure.